Abstract
In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Current Drug Targets
Title: Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Volume: 8 Issue: 1
Author(s): Jochen Wiesner and Hassan Jomaa
Affiliation:
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Abstract: In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Export Options
About this article
Cite this article as:
Wiesner Jochen and Jomaa Hassan, Isoprenoid Biosynthesis of the Apicoplast as Drug Target, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315551
DOI https://dx.doi.org/10.2174/138945007779315551 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews A Universal, Fully Automated High Throughput Screening Assay for Pyrophosphate and Phosphate Release from Enzymatic Reactions
Combinatorial Chemistry & High Throughput Screening AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Flexible Bronchoscopy Biopsy Tools and Techniques to Optimize Diagnostic Yield: A Contemporary Review
Current Respiratory Medicine Reviews Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Copper (II) – HisAibGly Complex and Its Superoxide Dismutase Activity (Suplementary Material)
Protein & Peptide Letters Targeting Folate Metabolism in the Human Malaria Parasite Plasmodium falciparum
Current Enzyme Inhibition Antibacterial Agents Targeting the Bacterial Cell Wall
Current Medicinal Chemistry Inhibitors of Multisubunit RNA Polymerases as Tools to Study Transcriptional Mechanisms in Prokaryotes and Eukaryotes
Current Chemical Biology Synthesis and Antimicrobial Activity of N,N-Bis(2-hydroxylbenzyl)-1,2- ethanediamine Derivatives
Letters in Drug Design & Discovery Synthesis of 1H-1,2,3-triazoles and Study of their Antifungal and Cytotoxicity Activities
Medicinal Chemistry Association of Low Vitamin D with Complications of HIV and AIDS: A literature Review
Infectious Disorders - Drug Targets Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science subject Index To Volume 2
Current Protein & Peptide Science Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry